



TBI-BH ECHO

Traumatic Brain Injury - Behavioral Health ECHO
UW Medicine | Psychiatry and Behavioral Sciences

Updates in Post-traumatic Headache

Natalia Murinova, MD

Amy Cuneo, MD

Tara Sharma, DO





Natalia Murinova MD
Clinical Professor

Director of Neurology
Headache Clinic



TBI-BH ECHO



Ami Cuneo MD

Assistant Professor
Neurology
Headache Clinic

ns for



TBI-BH ECHO



Tara Sharma, DO

**Clinical Assistant Professor
Headache Clinic**

ns for



TBI-BH ECHO

Disclosures

- None



Overview



Overview

- Definition of post-traumatic headache
- Pathophysiology (mild TBI/concussion)
- Different headache phenotypes
- Exacerbating factors
- Treatment modalities



Objectives

- Understand the most recent updates about the pathophysiology and epidemiology of post-traumatic headaches.
- Gain insight into how new medication and non-medication treatments work.
- Apply the newest medication and non-medication treatments to patients with post-traumatic headaches.



Overview

- **Definition of post-traumatic headaches**
- **Advances in post-traumatic headaches :**
 - Epidemiology
 - Pathophysiology
 - Treatments, including clinical applications of new treatments



Patient case



Adam



- ▶ Adam is coming to the medical center with chief complaint of headaches that worsened 3 days after he was hit by a car while cycling to UW
- ▶ He fell off the bicycle and was able to get back on the bike
- ▶ He had no LOC
- ▶ He has severe one-sided headache that is constant with nausea, light and sound sensitivity, and he has other medical issues such as disrupted sleep, dizziness, and others
- ▶ He is currently unable to bike due to fear of having another accident
- ▶ He has been taking daily acetaminophen (Tylenol) and seen multiple other providers; nothing is helping his symptoms



Adam would like to know his headache diagnosis

- ▶ Does Adam meet criteria for post-traumatic headache?



Question:

- ▶ Please enter on the chat is you think he meets PTH diagnosis
- ▶ If yes, why
- ▶ If no, why not



Definition of Post-Traumatic Headache



IHS CLASSIFICATION ICHD-3

7 days



TBI-BH ECHO

Definition of Post-Traumatic Headache



IHS CLASSIFICATION ICHD-3

- ▶ Secondary headache defined by the onset of headache or worsening of pre-existing headache within:
 - ▶ 7 days following trauma or injury,
 - ▶ Or 7 days after recovering consciousness,
 - ▶ And/or within 7 days after recovering the ability to sense and report pain

- ▶ In some studies, extension of the time interval beyond 7 days has been proposed, however currently it is 7 days



TBI-BH ECHO

Questions for Patient



IHS CLASSIFICATION ICHD-3

- ▶ Did your headache start or worsen within 7 days following trauma or injury?
- ▶ Did your headache start or worsen 7 days after recovering consciousness?
- ▶ Did your headache start or worsen 7 days after recovering the ability to sense and report pain?



TBI-BH ECHO

Persistent Post-Traumatic Headache



IHS CLASSIFICATION ICHD-3



Headache that resolves within 3 months of onset → acute PTH
Headache that persists beyond 3 months → persistent PTH



TBI-BH ECHO

Comment Re: Duration



IHS CLASSIFICATION ICHD-3

- ▶ How long is the duration of your new or worsening headache?
- ▶ Best is to ask for specific date of the accident and document this, instead of saying 3 months ago...




TBI-BH ECHO

Classification of Post-Traumatic Headache



Fig. 1: Classification of headache attributed to trauma or injury to the head.



Definition of Post-Traumatic Headache



IHS CLASSIFICATION ICHD-3

- ▶ PTH also includes headache attributed to whiplash or craniotomy



TBI-BH ECHO

Headache Phenotype



IHS CLASSIFICATION ICHD-3



TBI-BH ECHO

Headache Phenotype



IHS CLASSIFICATION ICHD-3

Once we determine that someone has PTH, we look into phenotype.

The most common PTH phenotypes are:

- Migraine-like headache
- Tension-type like headache
- Less common: cluster-type headache and cervicogenic headache (we will not address these in this lecture)



TBI-BH ECHO

Definition of Migraine



IHS CLASSIFICATION ICHD-3

Recurrent headache disorder manifesting in attacks lasting 4-72 hours. Typical characteristics of the headache are unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity and association with nausea and/or photophobia and phonophobia.

Diagnostic criteria:

- A. At least five attacks¹ fulfilling criteria B-D
- B. Headache attacks lasting 4-72 hr (untreated or unsuccessfully treated)^{2,3}
- C. Headache has at least two of the following four characteristics:
 - 1. unilateral location
 - 2. pulsating quality
 - 3. moderate or severe pain intensity
 - 4. aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)
- D. During headache at least one of the following:
 - 1. nausea and/or vomiting
 - 2. photophobia and phonophobia
- E. Not better accounted for by another ICHD-3 diagnosis.

Definition of Migraine



IHS CLASSIFICATION ICHD-3

Recurrent headache disorder manifesting in attacks lasting 4-72 hours. Typical characteristics of the headache are unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity and association with nausea and/or photophobia and phonophobia.

Diagnostic criteria:

- A. At least five attacks¹ fulfilling criteria B-D
- B. Headache attacks lasting 4-72 hr (untreated or unsuccessfully treated)^{2,3}
- C. Headache has at least two of the following four characteristics:
 - 1. unilateral location
 - 2. pulsating quality
 - 3. moderate or severe pain intensity
 - 4. aggravation by or causing avoidance of routine physical activity (eg, walking or climbing stairs)
- D. During headache at least one of the following:
 - 1. nausea and/or vomiting
 - 2. photophobia and phonophobia
- E. Not better accounted for by another ICHD-3 diagnosis.

This is a disabling condition that affects individuals in the prime of their lives.

Definition of Migraine with Aura



IHS CLASSIFICATION ICHD-3

- ▶ A. At least two attacks fulfilling criteria B and C
- ▶ B. One or more of the following fully reversible aura symptoms: visual, sensory, speech and/or language, motor, brainstem, retinal
- ▶ C. At least three of the following six characteristics:
 - ▶ At least one aura symptom spreads gradually over ≥ 5 minutes
 - ▶ Two or more aura symptoms occur in succession
 - ▶ Each individual aura symptom lasts 5-60 minutes
 - ▶ At least one aura symptom is unilateral
 - ▶ At least one aura symptom is positive
 - ▶ The aura is accompanied, or followed within 60 minutes, by headache
- ▶ D. Not better accounted for by another ICHD-3 diagnosis.



TBI-BH ECHO

Definition of Chronic Migraine



IHS CLASSIFICATION ICHD-3

- ▶ Headache occurring on 15 or more days/month for more than 3 months, which, on at least 8 days/month, has the features of migraine headache.



TBI-BH ECHO

Definition of Tension-Type Headache



IHS CLASSIFICATION ICHD-3

- ▶ A. Headache may last minutes to days (30 minutes to 7 days)
- ▶ B. Headache has at least 2 of the following characteristics:
 - ▶ -Bilateral location
 - ▶ -Pressing/tightening (non-pulsating) quality
 - ▶ -Mild or moderate intensity
 - ▶ -Not aggravated by routine physical activity
- ▶ C. Both of the following:
 - ▶ -No more than one of photophobia, phonophobia
 - ▶ -No nausea nor vomiting
- ▶ D. Not better accounted for by another ICHD-3 diagnosis.



TBI-BH ECHO

Case Presentation

Adam would like to know his headache diagnosis.



Adam: Review



- ▶ Adam is coming to the medical center with chief complaint of headaches that worsened 3 days after he was hit by a car while cycling to UW
- ▶ He fell off the bicycle and was able to get back on the bike
- ▶ He had no LOC
- ▶ He has severe one-sided headache that is constant with nausea, light and sound sensitivity, and he has other medical issues such as disrupted sleep, dizziness, and others
- ▶ He is currently unable to bike due to fear of having another accident
- ▶ He has been taking daily acetaminophen (Tylenol) and seen multiple other providers; nothing is helping his symptoms



Migraine Phenotype as an Example of PTH

- ▶ Adam meets criteria of both post-traumatic headache, and his headache phenotype is migraine type headache
- ▶ We enter both diagnoses of PTH and migraine in patient's chart
- ▶ Is his headache acute or persistent post-traumatic headache? Is this headache episodic or chronic migraine?



Migraine Phenotype as an Example of PTH

- ▶ We discuss the duration of the headache further with him.
- ▶ His headache is more than 3 months duration → persistent post-traumatic headache

AND

- ▶ His headaches occur daily → he has chronic migraine



Overview

- Definition of post-traumatic headaches
- Advances in post-traumatic headaches:
 - **Epidemiology**
 - Pathophysiology
 - Treatments, including clinical applications of new treatments



Epidemiology

nature reviews neurology

[Explore content](#) ▾ [About the journal](#) ▾ [Publish with us](#) ▾

[nature](#) > [nature reviews neurology](#) > [review articles](#) > [article](#)

Review Article | [Published: 16 September 2019](#)

Post-traumatic headache: epidemiology and pathophysiological insights

[Håkan Ashina](#), [Frank Porreca](#), [Trent Anderson](#), [Faisal Mohammad Amin](#), [Messoud Ashina](#), [Henrik Winther Schytz](#) & [David W. Dodick](#) 

[Nature Reviews Neurology](#) **15**, 607–617 (2019) | [Cite this article](#)

5248 Accesses | **74** Citations | **82** Altmetric | [Metrics](#)



Epidemiology

- Post-traumatic headaches
- Accounts for ~4% of all symptomatic headache disorders
- Headache is the most common sequelae of mild traumatic brain injury (mTBI) also known as concussion
- Estimate: 69 million people per year experience a traumatic brain injury (TBI) worldwide
- Patients with PTH commonly suffer from comorbidities such as anxiety and depression, both of which are among the leading causes of disability worldwide



Adam

- ▶ Adam is currently not working due to daily headaches, fatigue, low energy, anxiety, depression and a new fear regarding riding his bike.
- ▶ Adam would like to know what is his likelihood of being able to get back to work.



Epidemiology

- Among patients with PTH, 35% have not returned to work by 3 months after the injury (meaning 65% will return to work)
- Given that >3.8 million people are diagnosed with concussion in the USA annually
- The negative impact of PTH on work life and social activities is considerable

Adam would like to know what is his likelihood of being able to get back to work

- ▶ Adam would like to know his likelihood of being able to get back to work.
- ▶ 65% will return to work who had PTH by 3 months of injury.



Epidemiology

- The most common causes of TBI causing PTH
 - Traffic accidents (24-58%)
 - Falls (24-45%)
 - Sports (3-18%)
 - Violence (5-7%)
- About 40% of patients with TBI who reported acute PTH developed persistent PTH



Overview

- Definition of post-traumatic headaches
- Advances in post-traumatic headaches:
 - Epidemiology
 - **Pathophysiology**
 - Treatments, including clinical applications of new treatments



Pathophysiology

What are the updates in post-traumatic headache pathophysiology?

Possible disease mechanisms of PTH include:

- impaired descending modulation
- neurometabolic changes
- activation of the trigeminal sensory system



Pathophysiology

nature reviews **neurology**

[Explore content](#) ▾ [About the journal](#) ▾ [Publish with us](#) ▾

[nature](#) > [nature reviews neurology](#) > [review articles](#) > **article**

Review Article | [Published: 16 September 2019](#)

Post-traumatic headache: epidemiology and pathophysiological insights

[Håkan Ashina](#), [Frank Porreca](#), [Trent Anderson](#), [Faisal Mohammad Amin](#), [Messoud Ashina](#), [Henrik Winther Schytz](#) & [David W. Dodick](#) 

[Nature Reviews Neurology](#) **15**, 607–617 (2019) | [Cite this article](#)

5248 Accesses | **74** Citations | **82** Altmetric | [Metrics](#)

Ashina, H., Porreca, F., Anderson, T., Amin, F.M., Ashina, M., Schytz, H.W. and Dodick, D.W., 2019. Post-traumatic headache: epidemiology and pathophysiological insights. *Nature Reviews Neurology*, 15(10), pp.607



TBI-BH ECHO


Review Article

Posttraumatic Headache: Basic Mechanisms and Therapeutic Targets


Joshua Kamins, MD; Andrew Charles, MD 

Frequent or continuous headache, often refractory to medical therapy, is a common occurrence after head trauma. In addition to being the most common acute symptom after traumatic brain injury (TBI), headache is also one of the most persistent and disabling symptoms. Different studies indicate that 18-58% of those suffering a TBI will have significant headache at 1 year following the trauma. In addition to being disabling on its own, posttraumatic headache (PTH) is a predictor of overall outcome after concussion. Despite its remarkable prevalence and associated social and economic costs, many fundamental and important questions about PTH remain unanswered. The purpose of this review is to identify key questions regarding the clinical characteristics of posttraumatic headache, its basic mechanisms, and its optimal management. We discuss phenotypic features of PTH, pathophysiological mechanisms of TBI including potential overlaps with those of migraine and other primary headache disorders, and potential novel targets for treatment. We suggest different strategies to finding answers to the questions regarding PTH in order to advance the understanding of the disorder and develop more effective therapies.

Proposed Pathophysiology of Post-Traumatic Headache




a Impaired descending neuromodulation and activation of trigeminal and cervical afferents



Impaired Descending Neuromodulation

Ashina, H., Porreca, F., Anderson, T., Amin, F.M., Ashina, M., Schytz, H.W. and Dodick, D.W., 2019. Post-traumatic headache: epidemiology and pathophysiological insights. *Nature Reviews Neurology*, 15(10), pp.607





- release of glutamate
- excitatory neurotransmitters


Also:

- neurofilament collapse
- microtubule disassembly
→ causing axon damage


Ashina, H., Porreca, F., Anderson, T., Amin, F.M., Ashina, M., Schytz, H.W. and Dodick, D.W., 2019. Post-traumatic headache: epidemiology and pathophysiological insights. *Nature Reviews Neurology*, 15(10), pp.607



c Cortical spreading depression



d Calcitonin gene-related peptide-dependent mechanisms



- Calcitonin gene-related peptide (CGRP) release-dependent mechanisms
- CGRP is also involved in migraine



Advances in the understanding of the CGRP pathway in migraine

Prof Dr Lars Edvinsson

Dept of Medicine

Lund University

Lund, Sweden




CGRP changes are associated with migraine

- ▶ CGRP levels doubles with migraine
- ▶ The CGRP levels normalize after a triptan, BOTOX or new anti-CGRP treatment with migraine



CGRP Changes Are Associated with Migraine



Clinical studies where Dr. Edvinson And his team collected blood from External jugular vein of patients Coming to ED with severe headache And migraine attack, on the left all Patients had CGRP increase in Parallel with headache

Patients were treated with triptans, and after headache disappeared, the CGRP levels normalized. So there was a clear association of CGRP and migraine attack. VIP and substance P were not as involved.



Why is CGRP released during migraine?




CGRP- Calcitonin gene-related peptide

- ▶ Role in cardiovascular homeostasis
- ▶ Protects brain from hypertension
- ▶ Nociception
- ▶ In the heart, CGRP acts as a chronotrope by increasing heart rate
- ▶ Modulate the autonomic nervous system
- ▶ Plays a role in ingestion
- ▶ Has moderate effects on calcium homeostasis compared to its extensive actions in other areas, such as the autonomic nervous system




CGRP acts to protect against hypertension



Argunhan, F., Thapa, D., Aubdool, A.A., Carlini, E., Arkless, K., Hendrikse, E.R., de Sousa Valente, J., Kodji, X., Barrett, B., Ricciardi, C.A. and Gnudi, L., 2021. Calcitonin gene-related peptide protects against cardiovascular dysfunction independently of nitric oxide in vivo. *Hypertension*, 77(4), pp.1178-1190.


CGRP and asthma




- CGRP is synthesized and stored in C-fibers, neuroepithelial bodies (NEBs), and the epithelium.

Pavón-Romero, Gandhi F., Nancy Haydée Serrano-Pérez, Lizbeth García-Sánchez, Fernando Ramírez-Jiménez, and Luis M. Terán. "Neuroimmune pathophysiology in asthma." *Frontiers in cell and developmental biology* (2021): 1174.

e Neuroinflammation



Trigemino-cervical complex



What exacerbates Post-Traumatic Headaches?




What exacerbates post-traumatic headaches?

- ▶ Medication overuse headache
- ▶ Stress/ Mood
- ▶ Deconditioning
- ▶ Hormonal fluctuations in females
- ▶ Sleep disruption
- ▶ Lifestyle disruption
- ▶ PMH of migraine, mood disorders (depression/anxiety)
- ▶ FH of migraines and mood disorders



Treatments: Multimodal Approach



Review Article

Posttraumatic Headache: Basic Mechanisms and Therapeutic Targets

Joshua Kamins, MD; Andrew Charles, MD 

Frequent or continuous headache, often refractory to medical therapy, is a common occurrence after head trauma. In addition to being the most common acute symptom after traumatic brain injury (TBI), headache is also one of the most persistent and disabling symptoms. Different studies indicate that 18-58% of those suffering a TBI will have significant headache at 1 year following the trauma. In addition to being disabling on its own, posttraumatic headache (PTH) is a predictor of overall outcome after concussion. Despite its remarkable prevalence and associated social and economic costs, many fundamental and important questions about PTH remain unanswered. The purpose of this review is to identify key questions regarding the clinical characteristics of posttraumatic headache, its basic mechanisms, and its optimal management. We discuss phenotypic features of PTH, pathophysiological mechanisms of TBI including potential overlaps with those of migraine and other primary headache disorders, and potential novel targets for treatment. We suggest different strategies to finding answers to the questions regarding PTH in order to advance the understanding of the disorder and develop more effective therapies.

Kamins, J. and Charles, A., 2018. Posttraumatic headache: basic mechanisms and therapeutic targets. *Headache: The Journal of Head and Face Pain*, 58(6), pp.811-826.



Memantine (Namenda)



Memantine (Namenda)



- Inhibitor of the NMDA subtype of glutamate receptors
- Glutamate is the primary excitatory neurotransmitter in CNS
- Since an increase in glutamate occurs in the early response to trauma, early treatment may therefore be important.

Kamins, J. and Charles, A., 2018. Posttraumatic headache: basic mechanisms and therapeutic targets. *Headache: The Journal of Head and Face Pain*, 58(6), pp.811-826.



If migraine-like headache, treat like migraine

Sinus
pain is
behind
browbone
and/or
cheekbone.



Cluster
pain is
in and
around
one eye.



Tension
pain is
like a
band
squeezing
the head.



Migraine
pain, nausea
and visual
changes are
typical of
classic form.



Treatments: Preventive

- When to start a preventive medication?
 - Decision based upon:
 - Number of headache days per month
 - Disability (as based on MIDAS, MPFID, or HIT)

Received: 15 March 2021 | Accepted: 9 May 2021

DOI: 10.1111/head.14133

AHS CONSENSUS STATEMENT

The American Headache Society Consensus Statement: Update on Integrating new migraine treatments into clinical practice

Jessica Ailani MD¹ | Rebecca C. Burch MD² | Matthew S. Robbins MD³ | on behalf of the Board of Directors of the American Headache Society⁴

TABLE 4 Criteria for identifying patients for preventive treatment⁸

Prevention should be ...	Headache days/month	Degree of disability required ^a
Offered	6 or more	None
	4 or more	Some
	3 or more	Severe
Considered	1 or 5	None
	3	Some
	2	Severe

^aAs can be measured by the Migraine Disability Assessment Scale, Migraine Physical Function Impact Diary, or Headache Impact Test.

Treatments: Preventive

- What are the updated preventive medications?

TABLE 6 Medications with evidence of efficacy in migraine prevention^{a,20,25}

Established efficacy ^b		Probably effective ^c	
Oral	Parenteral	Oral	Parenteral
Candesartan	Eptinezumab (IV)	Amitriptyline	OnabotulinumtoxinA + CGRP mAb ^{d,e}
Divalproex sodium	Fronumab (SQ)	Atenolol	
Frovatriptan ^f	Fremanezumab (SQ)	Lisinopril	
Metoprolol	Galcanezumab (SQ)	Memantine	
Propranolol	OnabotulinumtoxinA ^d (SQ)	Nadolol	
Limolol		Venlafaxine	
Topiramate			
Valproate sodium			

Rimegepant (1 tab every other day)

Atogepant (1 tab daily)



Treatments: Preventive

- What are the updated preventive medications?

TABLE 6 Medications with evidence of efficacy in migraine prevention^{a,20,25}

Established efficacy ^b		Probably effective ^c	
Oral	Parenteral	Oral	Parenteral
Candesartan	Eptinezumab (IV)	Amitriptyline	OnabotulinumtoxinA + CGRP mAb ^{d,c}
Divalproex sodium	Fronumab (SQ)	Atenolol	
Frovatriptan ^f	Fremanezumab (SQ)	Lisinopril	
Metoprolol	Galcanezumab (SQ)	Memantine	
Propranolol	OnabotulinumtoxinA ^d (SQ)	Nadolol	
Timolol		Venlafaxine	
Topiramate			
Valproate sodium			


Rimegepant (1 tab every other day)
Atogepant (1 tab daily)

↑ CGRP antagonists

↑ Anti-CGRP monoclonal antibodies



Treatments: Multimodal Approach



Treatments: Neuromodulation

- **Use as stand-alone or add-on treatment for migraine**
 - Stimulate the nervous system centrally or peripherally with an electric current
 - FDA-approved for migraine



CEFALY

- Age ≥ 18
- Acute and preventive treatment
- Mechanism:
 - Stimulates trigeminal nerve

Nerivio



- Age ≥ 12
- Acute treatment
- Mechanism:
 - Remote electrical neuromodulation affecting descending inhibitory pain pathways brainstem

Relivion



- Age ≥ 18
- Acute treatment
- Mechanism:
 - Stimulates trigeminal and occipital nerves



GammaCore

- Age ≥ 12
- Acute treatment
- Mechanism:
 - Stimulates vagus nerve




Treatments: Neuromodulation

- **CEFALY**

- Normalizes brain function in medial frontal cortical areas controlling affective and cognitive dimensions of pain



CEFALY



Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial

Copyright © 2019, Vol. 39(1), 1-11
DOI: 10.1186/s12928-019-0550-0
This article is licensed under a Creative Commons Attribution 4.0 International License
http://creativecommons.org/licenses/by/4.0/

Denise E Chou¹, Marianna Shnayderman Yuzakli¹, Dana Winegarner², Vernon Rowe³, Debra Karvilia³ and Jean Schoenen⁴


Treatments: Neuromodulation

• CEFALY


- Normalizes brain function in medial frontal cortical areas controlling affective and cognitive dimensions of pain



CEFALY



Acute Management



Preventive Management

Treatments: Neuromodulation

Original Research | Open Access | Published: 04 June 2022

External Concurrent Occipital and Trigeminal Neurostimulation Relieves Migraine Headache: A Prospective, Randomized, Double-Blind, Sham-Controlled Trial

David Canal, Stewart J. Tepper, Lisa Deutsch & Ron Sharron

Pain and Therapy 11: 907–921 (2022)

• Relivion


- Combined trigeminal nerve -occipital nerve stimulator
- ? More effective at decreasing holocephalic pain
 - Episodic and chronic migraine subjects ($N=55$)
 - Randomized to active ($n=27$) or sham ($n=28$) treatment



Relivion

• Results

- Active stimulation was more effective than sham stimulation at 1 hour (53% vs 10%), 2 hours (52% vs 17%) and 24 hours (71 vs 34%)
- Comparable to triptans



Treatments: Neuromodulation

Which patients should use these devices?



Treatments: Neuromodulation

Which patients should use these devices?

- Patients who are looking to **bolster their acute and preventive approaches** for treatment of migraine
- Patients **at risk for medication overuse** headache (due to headache or other body pain)
- Patients who prefer not to use medications/injections
- Patients with **medical conditions** preventing them from taking traditional medications for headache
- Patients who have **limited access/interest in acute care services** for severe headache



Treatments: Neuromodulation

What are the side effects and contraindications?

Side effects:

- Intolerance to feeling of CEFALY on the forehead: 1.25%
- Fatigue during / after the session: 0.65%
- Headache after one session: 0.52%
- Irritation of the skin on the forehead: 0.22%

Contraindications:

- Implanted metallic / electronic device in head
- Pain of unknown origin
- A cardiac pacemaker or implanted or wearable defibrillator (may cause interference with pacing, electric shock, or death)



TBI-

Treatments: Neuromodulation

What are the side effects and contraindications?

Often not covered by insurance

Side effects:

- Intolerance to feeling of CEFALY on the forehead: 1.25%
- Fatigue during / after the session: 0.65%
- Headache after one session: 0.52%
- Irritation of the skin on the forehead: 0.22%

Contraindications:

- Implanted metallic / electronic device in head
- Pain of unknown origin
- A cardiac pacemaker or implanted or wearable defibrillator (may cause interference with pacing, electric shock, or death)



TBI-

Adam



- ▶ Adam is coming to the medical center with chief complaint of headaches that worsened 3 days after he was hit by a car while cycling to UW
- ▶ He fell off the bicycle and was able to get back on the bike
- ▶ He had no LOC
- ▶ He has severe one-sided headache that is constant with nausea, light and sound sensitivity, and he has other medical issues such as disrupted sleep, dizziness, and others
- ▶ He is currently unable to bike due to fear of having another accident
- ▶ He has been taking daily acetaminophen (Tylenol) and seen multiple other providers; nothing is helping his symptoms



Adam



- ▶ Adam has been taking daily acetaminophen (Tylenol) and nothing is helping his symptoms



Adam



- ▶ Adam has been taking daily acetaminophen (Tylenol) and nothing is helping his symptoms
- ▶ What other condition is important to diagnose and treat?




Medication Overuse Headache

- Develops in individuals with pre-existing headaches (e.g., migraine or tension type headache)
- Headache increases in frequency to ≥ 15 days per month
- Caused by acute medication use on ≥ 10 or 15 days/month (depending on medication) for > 3 months



How does Medication Overuse affect Brain?



Grazzi, Licia, et al. "Chronic migraine with medication overuse pre-post withdrawal of symptomatic medication: clinical results and fMRI correlations." *Headache: The Journal of Head and Face Pain* 50.6 (2010): 998-1004.


- **Functional brain imaging**
 - Hypometabolism in several brain structures
 - Withdrawal from overused medications shows **reversible changes** to a large extent in these areas



Medication overuse headache

How much acute medication is safe?

- The amount of acute medication “allowed” varies from person to person
- International Classification of Headache Disorders
 - Non-opiates: 15+ days/month in combination
 - Opiates +/- non-opiates: 10+ days/month
 - Triptans: 10+ days/month
- However, as few as 6-8 days per month can cause MOH in patients with anxiety/stressors



≥ 10 or ≥ 15
days per
month

4-9 days per
month

<4 days per
month



Supplements



Acute

Acute and preventive



Preventive



Preventive



Preventive



Neuromodulation



Cefaly



Nerivio



gammaCore




Use Multimodal approach



Sleep



Exercise



Biofeedback/relaxation



Anti-
Inflammatory
Nutrition



Summary

- Use a multi-modal approach, incorporate medications for PTH, evidence-based supplements, neuromodulation devices, and lifestyle changes
- Neuromodulation devices
 - Not covered typically covered by insurance
 - Safe, non-medication approaches that are as effective as medication



References

- ▶ Ashina, H., Porreca, F., Anderson, T., Mohammad Amin, F., Ashina, M., Winther Schytz, H., & Dodick, D. W. (2019). Post-traumatic headache: epidemiology and pathophysiological insights. *Nature Reviews Neurology*, 15(10), 607-617.
- ▶ Josh Kamins and Charles Andrews. Post traumatic headache. Basic Mechanisms and therapeutic targets
- ▶ ICHD3 criteria
- ▶ Hoffman, Jeanne et. al. Natural history of headache after TBI
- ▶ Nikolai Bogduk. Cervicogenic headache: Anatomic basis and pathophysiologic mechanisms
- ▶ Michael Severson and Margaret Strecker-McGraw. Cerebrospinal Fluid Leak. November 2020.
- ▶ Safavi-Naeini and Mehdi Razavi. Postural orthostatic Tachycardia Syndrom



Questions?

